Trial Search Results

Treatment With Namenda in Women at Risk for Cognitive Decline

This research aims to explore the effectiveness of memantine (Namenda) in treating post-menopausal women between the ages of 50 and 65, who are at risk for cognitive decline. Memantine has already been shown to offer cognitive benefits to patients suffering from Alzheimer's disease, but it's potential for treating those at risk for cognitive decline without Alzheimer's disease or other dementia has yet to be evaluated. It is possible that memantine may offer neurocognitive benefits to this population, as well. Participants are asked to take medication for six months, complete neuropsychological testing, and one blood draw.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: Forest Laboratories

Stanford Investigator(s):

Intervention(s):

  • Drug: Namenda

Phase:

N/A

Eligibility


Inclusion Criteria::

   - Women between the ages of 50-65

   - Willing to sign Human Subjects Protection Consent Form

   - Personal or family history of mood disorder

   - Hypothyroidism

   - Diabetes

   - Family history of Alzheimer's disease Exclusion Criteria:- Possible or probable
   Alzheimer's disease or dementia

   - History of cerebrovascular disease

   - History of myocardial infarction within the previous year

   - History of unstable heart disease

   - Uncontrolled hypertension

   - Less than 8 years of education

   - English as a 2nd language

   - Uncorrected vision or hearing deficits

Ages Eligible for Study

50 Years - 65 Years

Genders Eligible for Study

Female

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting